Search

Your search keyword '"Matthews, David R."' showing total 750 results
Start Over Author "Matthews, David R."
750 results on '"Matthews, David R."'

6. Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control

Author

Tremblay, Johanne, Haloui, Mounsif, Attaoua, Redha, Tahir, Ramzan, Hishmih, Camil, Harvey, François, Marois-Blanchet, François-Christophe, Long, Carole, Simon, Paul, Santucci, Lara, Hizel, Candan, Chalmers, John, Marre, Michel, Harrap, Stephen, Cífková, Renata, Krajčoviechová, Alena, Matthews, David R., Williams, Bryan, Poulter, Neil, Zoungas, Sophia, Colagiuri, Stephen, Mancia, Giuseppe, Grobbee, Diederick E., Rodgers, Anthony, Liu, Liusheng, Agbessi, Mawussé, Bruat, Vanessa, Favé, Marie-Julie, Harwood, Michelle P., Awadalla, Philip, Woodward, Mark, Hussin, Julie G., and Hamet, Pavel

Published
2021
Full Text
View/download PDF

16. Correction to: Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control

Author

Tremblay, Johanne, Haloui, Mounsif, Attaoua, Redha, Tahir, Ramzan, Hishmih, Camil, Harvey, François, Marois-Blanchet, François-Christophe, Long, Carole, Simon, Paul, Santucci, Lara, Hizel, Candan, Chalmers, John, Marre, Michel, Harrap, Stephen, Cífková, Renata, Krajčoviechová, Alena, Matthews, David R., Williams, Bryan, Poulter, Neil, Zoungas, Sophia, Colagiuri, Stephen, Mancia, Giuseppe, Grobbee, Diederick E., Rodgers, Anthony, Liu, Liusheng, Agbessi, Mawussé, Bruat, Vanessa, Favé, Marie-Julie, Harwood, Michelle P., Awadalla, Philip, Woodward, Mark, Hussin, Julie G., and Hamet, Pavel

Published
2021
Full Text
View/download PDF

35. Authors' reply

Author

Karagiannis, Thomas, Paschos, Paschalis, Paletas, Konstantinos, and Matthews, David R

Published
2012

38. Sodium‐glucose co‐transporter‐2 inhibitors: A paradigm shift in treatment for type 2 diabetes.

Author

Matthews, David R.

Subjects
*PATHOLOGY, *TYPE 2 diabetes, *GLUCAGON-like peptide-1 receptor, *MAJOR adverse cardiovascular events, *EXENATIDE, *GLYCEMIC control
Abstract

This article discusses the paradigm shift in the treatment of type 2 diabetes with the introduction of sodium-glucose co-transporter-2 inhibitors (SGLT2is). The use of SGLT2is has led to a change in attitude and therapeutics for type 2 diabetes, as it has been found to improve outcomes in cardiovascular disease, heart failure, and renal disease. The article highlights the findings from the CANVAS Program and the CREDENCE trial, which demonstrate the benefits of canagliflozin in reducing major adverse cardiovascular events and ameliorating renal function. These findings have led to updated guidelines recommending SGLT2is as first-line therapy for type 2 diabetes with cardiovascular disease or high cardiovascular risk. The article emphasizes the importance of considering the broader evidence, including real-world evidence, in understanding the specific effects of SGLT2is. Overall, the use of SGLT2is represents a significant revolution in the treatment of type 2 diabetes. [Extracted from the article]

Published
2024
Full Text
View/download PDF

46. Reasons for hospitalizations in patients with type 2 diabetes mellitus in the CANVAS Program: a secondary analysis

Author

Feng, Kent Y, Li, JingWei, Ianus, Juliana, de Zeeuw, Dick, Fulcher, Greg R, Pfeifer, Michael, Matthews, David R, Jardine, Meg J, Perkovic, Vlado, Neal, Bruce, Mahaffey, Kenneth W, and Groningen Kidney Center (GKC)

Abstract

AIMS: To determine the reasons for hospitalizations in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program and the effects of the sodium glucose co-transporter 2 inhibitor canagliflozin on hospitalization. MATERIALS AND METHODS: A secondary analysis was performed on the CANVAS Program that included 10,142 participants with type 2 diabetes mellitus randomized to canagliflozin or placebo. The primary outcome was total (first plus all recurrent) all-cause hospitalization (ACH). Secondary outcomes were total hospitalizations categorized by the Medical Dictionary for Regulatory Activities hierarchy at the system organ class level, reported by investigators at each center. Outcomes were assessed using negative binomial models. RESULTS: Of the 7115 hospitalizations reported, the most common reasons were cardiac disorders (23.7%), infections and infestations (15.0%), and nervous system disorders (9.0%). The rate of total ACH was lower in the canagliflozin group (n=5795) compared to the placebo group (n=4347): 197.9 versus 215.8 participants per 1000 patient-years, respectively (rate ratio [RR] 0.92; 95% confidence interval [CI] 0.86, 0.98). Canagliflozin reduced the rate of total hospitalizations due to cardiac disorders (RR 0.81; 95% CI 0.75, 0.88). There was no significant difference between the canagliflozin and placebo groups in the rates of total hospitalizations due to infections and infestations (RR 0.96; 95% CI 0.86, 1.02) or nervous system disorders (RR 0.96; 95% CI 0.88, 1.05). CONCLUSIONS: In the CANVAS Program, the most common reasons for hospitalization were cardiac disorders, infections and infestations, and nervous system disorders. Canagliflozin, compared with placebo, reduced the rate of total ACH. This article is protected by copyright. All rights reserved.

Published
2021

48. Glycaemia And Vascular Effects Of Type 2 Diabetes

Author

Budenholzer, Brian, Cruickshank, J. K., Jarrett, R. J., Stratton, Irene M., Cull, Carole A., Manley, Susan E., Adler, Amanda I., Neil, H. Andrew W., Matthews, David R., and Holman, Rury R.

Published
2001

Catalog

Books, media, physical & digital resources
See catalog results